NZ530554A - Neuronutrients - Google Patents
NeuronutrientsInfo
- Publication number
- NZ530554A NZ530554A NZ53055404A NZ53055404A NZ530554A NZ 530554 A NZ530554 A NZ 530554A NZ 53055404 A NZ53055404 A NZ 53055404A NZ 53055404 A NZ53055404 A NZ 53055404A NZ 530554 A NZ530554 A NZ 530554A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- range
- derivative
- group
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims abstract description 91
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 14
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 13
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 8
- 229960000367 inositol Drugs 0.000 claims abstract description 8
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 8
- MLAUVUHGQARGDU-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.CC1=NC=C(CO)C(CO)=C1O MLAUVUHGQARGDU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 24
- 229910052751 metal Inorganic materials 0.000 claims description 24
- 239000002184 metal Substances 0.000 claims description 24
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 22
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 21
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 20
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 14
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 13
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 12
- 229960001231 choline Drugs 0.000 claims description 12
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 12
- 235000019152 folic acid Nutrition 0.000 claims description 12
- 229960000304 folic acid Drugs 0.000 claims description 12
- 239000011724 folic acid Substances 0.000 claims description 12
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 229960004441 tyrosine Drugs 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 244000146462 Centella asiatica Species 0.000 claims description 8
- 235000004032 Centella asiatica Nutrition 0.000 claims description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 8
- 239000012676 herbal extract Substances 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 235000015418 Bacopa monnieria Nutrition 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229930182816 L-glutamine Natural products 0.000 claims description 6
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 claims description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 6
- 150000002739 metals Chemical class 0.000 claims description 6
- 229960001682 n-acetyltyrosine Drugs 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 244000187129 Bacopa monnieria Species 0.000 claims description 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 240000004160 Capsicum annuum Species 0.000 claims description 5
- 235000002567 Capsicum annuum Nutrition 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229910052796 boron Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940046001 vitamin b complex Drugs 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229940087603 grape seed extract Drugs 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229940124277 aminobutyric acid Drugs 0.000 claims description 2
- 150000001669 calcium Chemical class 0.000 claims description 2
- 229940047036 calcium ascorbate Drugs 0.000 claims description 2
- 235000010376 calcium ascorbate Nutrition 0.000 claims description 2
- 239000011692 calcium ascorbate Substances 0.000 claims description 2
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 2
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 2
- 229960004874 choline bitartrate Drugs 0.000 claims description 2
- 150000001844 chromium Chemical class 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229940102465 ginger root Drugs 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 150000002680 magnesium Chemical class 0.000 claims description 2
- 150000002696 manganese Chemical class 0.000 claims description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002751 molybdenum Chemical class 0.000 claims description 2
- 229940116351 sebacate Drugs 0.000 claims description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims description 2
- 229940082569 selenite Drugs 0.000 claims description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 239000001841 zingiber officinale Substances 0.000 claims description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 54
- 239000002858 neurotransmitter agent Substances 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 24
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 22
- 229960004373 acetylcholine Drugs 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 210000004958 brain cell Anatomy 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 13
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000015654 memory Effects 0.000 description 11
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 230000003925 brain function Effects 0.000 description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 235000011201 Ginkgo Nutrition 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- -1 phospholipids phosphatidyl inositol Chemical class 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 229930003779 Vitamin B12 Natural products 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 235000003969 glutathione Nutrition 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 235000019163 vitamin B12 Nutrition 0.000 description 6
- 239000011715 vitamin B12 Substances 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 229940011671 vitamin b6 Drugs 0.000 description 6
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 235000008160 pyridoxine Nutrition 0.000 description 5
- 239000011677 pyridoxine Substances 0.000 description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 210000003007 myelin sheath Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 230000036626 alertness Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000000446 fuel Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 241000555825 Clupeidae Species 0.000 description 2
- 241001454694 Clupeiformes Species 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001090156 Huperzia serrata Species 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- 230000007000 age related cognitive decline Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000019513 anchovy Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000002012 ayurvedic medicine Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 2
- 239000011678 thiamine pyrophosphate Substances 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VKPHHYUEMRNFSX-UHFFFAOYSA-N 2-aminobutan-2-ol Chemical compound CCC(C)(N)O VKPHHYUEMRNFSX-UHFFFAOYSA-N 0.000 description 1
- XMLHTAFIAXPIDG-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;manganese(3+) Chemical compound [Mn+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XMLHTAFIAXPIDG-UHFFFAOYSA-K 0.000 description 1
- ZJCYPPVQKGHKQK-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methyl-pyridin-3-ol Chemical compound CC1=NC=C(CO)C(CO)=C1O.CC1=NC=C(CO)C(CO)=C1O ZJCYPPVQKGHKQK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- KUDUMIJONPZUKY-UHFFFAOYSA-K C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[B+3] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[B+3] KUDUMIJONPZUKY-UHFFFAOYSA-K 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001504070 Huperzia Species 0.000 description 1
- 241000482467 Huperzia chinensis Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 240000007948 Mecardonia procumbens Species 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000015123 black coffee Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- VYZAMTAEIAYCRO-YPZZEJLDSA-N chromium-50 Chemical compound [50Cr] VYZAMTAEIAYCRO-YPZZEJLDSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- WGKSVGIFYJXABK-UHFFFAOYSA-L copper;decanedioate Chemical compound [Cu+2].[O-]C(=O)CCCCCCCCC([O-])=O WGKSVGIFYJXABK-UHFFFAOYSA-L 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009177 electrical depolarization Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229940032582 grape seed extract 25 mg Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000007595 memory recall Effects 0.000 description 1
- 230000007104 mental stamina Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229940079458 niacinamide 50 mg Drugs 0.000 description 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- HYISVWRHTUCNCS-UHFFFAOYSA-N pyrene-1-carboxylic acid Chemical compound C1=C2C(C(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 HYISVWRHTUCNCS-UHFFFAOYSA-N 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- WWRJFSIRMWUMAE-ZZMNMWMASA-L zinc;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate Chemical compound [Zn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] WWRJFSIRMWUMAE-ZZMNMWMASA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A neuronutrient health supplement composition comprising pyridoxine alpha ketoglutarate, acetyl L-carnitine, an extract of ginkgo biloba and at least one plasmogen phosphalide, at least one inositol.
Description
New Zealand Paient Spedficaiion for Paient Number 530554
Patents Form # 5
530 5 5 4
INTELLECTUAL PROPERTY OFFICE OF N.Z
1 2 JAN 20(ft RECEIVED
NEW ZEALAND
Patents Act 1953
COMPLETE SPECIFICATION
TITLE :
Neuronutrients
I, AL-SHAKARCHI, A. Munem Mohammad Daoud
Address: 4 Landsberg Way, Windsor Park, Mairangi Bay, Auckland, New Zealand Nationality: A New Zealand citizen do hereby declare the invention for which I pray that a patent may be granted to me and the method by which it is to be performed, to be particularly described in and by the following statement:
- 1
PF05.JWP
FEE CODE 1050
FIELD OF THE INVENTION
The present invention relates to a health supplement, in particular to a health supplement to aid brain function and memory.
BACKGROUND
In order to function optimally, the brain needs the proper nutrients, which may be compromised in the modern world. The pressures of daily life make it difficult for modern Americans to devote the necessary time to prepare food properly. As a consequence of this and a constant barrage of advertising, a high proportion of many people's diets consist of fast foods and packaged foods, low in many essential nutrients and high in sodium and sugar. 10 Excess sodium can create a relative imbalance in the sodium/potassium ratio, and potassium is an important nutrient for nerve conduction. Excess simple sugar intake can, paradoxically, cause low blood sugar, thus depriving the brain of the fuel it needs.
Ultimately, all of the health and nutrition issues indeed, all the issues of any kind that we face begin and end with the brain. The body attests to the brain's importance by devoting a 15 huge share of its vital nutritional resources to the care and feeding of this single, and singular, organ. Knowing what the nutritional issues associated with optimal brain nutrition are supporting the brain's production of energy, providing the raw materials for the production and utilization of neurotransmitters, protecting the brain's delicate structures, and supporting the structure of the brain's cell membranes can help you make informed choices 20 about your nutritional needs.
It is an object of the present invention to provide a health supplement to aid brain and memory function. One of the keys to supporting memory power is to give the brain the foods it needs not only to run properly, but also to operate better. One name for these brain foods is neuronutrients—specific vitamins, minerals, fatty acids, amino acids, and trace elements 25 essential to brain function. It is an object of the present invention top provide such neuronutrients and it is yet a further object of the invention to provide such neuronutrients in tablet form.
130110NZ Prov.doc/CA/ca
STATEMENTS OF THE INVENTION
A composition suitable for administering to warm blooded animals as a health supplement including pyridoxine alpha ketoglutarate and acetyl L-carnitine wherein the composition further includes at least one plasmalogen phosphalide, one or more inositols, and extract of 5 ginkgo biloba.
Preferably, the or each plasmalogen phosphalide can be selected from the group comprising phosphatidyl choline and phosphatidyl ethanolamine.
Preferably the or each inositol can be selected from the group comprising phosphatidyl inositol and inositol.
Preferably the composition further comprises vitamins.
More preferably still, the vitamins can be selected from the group comprising A, C, E and a B complex.
More preferably the vitamin B complex can be selected from the group comprising Bl, B2, B3, B5, B6 and B12.
Preferably, the composition further comprises a metal derivative.
Preferably, the metal derivative can be selected from the group comprising mono, di, tri and tetra valent metal derivatives.
More preferably still, the divalent metal derivative can be selected from the group of metals comprising calcium, zinc, copper, manganese, chromium and magnesium.
More preferably still, the divalent metal derivative can be selected from the group comprising calcium ascorbate, carbonate, nicotinate, sebacate, chloride, malate, taurinate, oxide,citrate or succinate.
Preferably, the trivalent metal derivative can be selected from the group of metals comprising boron and chromium.
More preferably still, the trivalent metal derivatives can be selected from the group comprising chloride, nicotinate and citrate.
130110NZ Prov.doc/CA/ca
INTELLECTUAL PROPERTY OPPICP OF N.Z
2 8 JAN 2004 RECEIVED
Preferably, the monovalent metal derivative can be selected from the group of metals comprising potassium, sodium and lithium.
More preferably, the monovalent metal derivatives can be selected from the group comprising selenite and molybdate.
Preferably, the composition further comprises an amino acid.
More preferably still, the amino acid can be selected from the group comprising L-glutamine, Taurine, N-acetyl L-Tyrosine, and L-Tyrosine.
Preferably, the composition further comprises at least one of the following, L-Pyroglutamic acid, dimethylaminoethanolbitartrate, DL-phenylalanine, choline bitartrate, liopic acid, 10 docosahexaenoic acid, folic acid, biotin, huperzine and/or phosphatidyl serine.
Preferably, the composition further comprises one or more herbal extracts.
More preferably still, the herbal extracts can be selected from the group comprising Siberian ginseng, gotu kola, ginger root, schizandra, cayenne, grape seeds extract, bacopa monniera and rosemary.
Preferably, the composition further comprises an excipient.
Preferably, the extract of Ginkgo biloba is in the range of 1.0-5.0 x 10-3 %w/v.
Preferably, the pyridoxine alpha ketoglutarate is in the range of 10-30 x 10-3 %w/v. Preferably, the acetyl L-carnitine is in the range of 40-150 x 10-3 %w/v.
Preferably, the plasmalogen phosphalide is in the range of 50-200 x 10-3 %w/v. 20 Preferably, the phosphatidyl choline is in the range of 40-150 x 10-3 %w/v.
Preferably, the phosphatidyl ethanolamine is in the range of 5-40 x 10-3 %w/v.
Preferably, the inositol is in the range of 5-50 x 10-3 %w/v.
Preferably, the phosphatidyl inositol is in the range of 5-50 x 10-3 %w/v.
130110NZ Prov.doc/CA/ca
INTELLECTUAL PROPERTY OFFICE OF N.Z
2 8 JAN 2004 RECEIVED
Preferably, the vitamin B complex is in the range of 30-150 x 10-3 %w/v.
Preferably, the vitamin A is in the range of 2-20 x 10-4 %w/v.
Preferably, the vitamin C is in the range of 5-30 x 10-3 %w/v.
Preferably, the folic acid is in the range of 100-600 x 10-3 %w/v.
Preferably, the botin is in the range of 20-80 x 10-3 %w/v.
Preferably, the calcium derivative is in the range of 20-80 x 10-3 %w/v Preferably, the magnesium derivative is in the range of 20-80 x 10-3 %w/v. Preferably, the zinc derivative is in the range of 3-15 x 10-3 %w/v.
Preferably, the manganese derivative is in the range of 2-8 x 10-3 %w/v. 10 Preferably, the selenium is in the range of 20-80 x 10-3 %w/v.
Preferably, the boron derivative is in the range of 100-400 x 10-3 %w/v.
Preferably, the copper derivative is in the range of 1-8 x 10-4 %w/v Preferably, the molybdenum derivative is in the range of 7-40 x 10-3 %w/v. Preferably, the chromium derivative is in the range of 20-80 x 10-3 %w/v. 15 Preferably, the L-Pyroglutamic acid is in the range of 20-120 x 10-3 %w/v. Preferably, the L-glutamine is in the range of 20-160 x 10-3 %w/v.
Preferably, the acetyl L-carnitine is in the range of 20-160 x 10-3 %w/v.
Preferably, the L-cartinine is in the range of 40-160 x 10-3 %w/v.
Preferably, the dimethylaminoethanolbitartrate is in the range of 10-60 x 10-3 %w/v. 20 Preferably, the taurine is in the range of 5-50 x 10-3 %w/v.
Preferably, the DL phenylalanine is in the range of 5-50 x 10-3 %w/v.
130110NZ Prov.doc/CA/ca
Preferably, the choline is in the range of 20-50 x 10-3 %w/v.
Preferably, the N-acetyl L-tyrosine is in the range of 20-120 x 10-3 %w/v.
Preferably, the L tyrosine is in the range of 20-120 x 10-3 %w/v.
Preferably, the gama amino butyric acid is in the range of 5-50 x 10-3 %w/v.
Preferably, the lipoic acid is in the range of 3-15 x 10-3 %w/v.
Preferably, the phsphatidyl serine is in the range of 7-40 x 10-3 %w/v.
Preferably, the docosahexaenoic acid is in the range of 8-30 x 10-3 %w/v.
Preferably, the huperzine is in the range of 7-40 x 10-3 %w/v.
Preferably, the Siberian Ginseng is in the range of 7-40 x 10-3 %w/v.
Preferably, the Gotu Kola is in the range of 7-40 x 10-3 %w/v.
Preferably, the Ginger Root is in the range of 7-40 x 10-3 %w/v.
Preferably, the Schizandra is in the range of 7-40 x 10-3 %w/v.
Preferably, the cayenne is in the range of 7-40 x 10-3 %w/v.
Preferably, the grape seed extract is in the range of 7-40 x 10-3 %w/v.
Preferably, the bacopa monniera or rosemary is in the range of 15-60 x 10-3 %w/v. The present embodiment is shown by way of example only.
DESCRIPTION OF THE PREFEERED EMBODIENTS.
ACETYL L-CARNITINE
Acetyl 1-carnitine (ALC) is an important neuroceutical with a variety of beneficial effects on 20 the brain and body. ALC, an acetylated amino acid, has a high degree of structural similarity to the neurotransmitter acetylcholine (ACH) and facilitates the transport of metabolic energy. Animal studies have shown that ALC promotes the synthesis and release of ACH, helps to
130110NZ Prov.doc/CA/ca
prevent the accumulation of damaging lipofuscin in brain cells , enhances the stability of cell membranes, and helps protect the brain from free-radical damage by increasing amounts of the potent antioxidant, glutathione. Another major function of ALC is to transport long-chain fatty acids into mitochondria, providing an important energy source for tissues that burn fat 5 for energy, such as muscle.
Acetyl 1-carnitine facilitates the transfer of metabolic energy by acting as carrier for acetyl groups across cell membranes. Acetyl groups are energy-carrying organic molecules that can be transferred to the coenzyme acetyl CoA, which forms the starting point of the central energy-generation process called the Krebs cycle. Aside from its central role in cellular 10 energy production, acetyl CoA, along with choline, is a precursor for the neurotransmitter acetylcholine. ACH is one of the most abundant neurotransmitters in the body, and is necessary for memory and muscle control. ALC promotes the production of acetylcholine both by transferring acetyl groups to acetyl CoA and by inducing the activity of choline acetyltransferase, an enzyme that manufactures acetylcholine by attaching an acetyl group 15 from acetyl CoA onto the choline molecule. ALC has also been shown in animal studies to stimulate a class of neurotransmitter receptors called muscarinic acetylcholine receptors, thus further enhancing the activity of ACH in the brain.
Damaged brain neurons are characterized by a decreased ability to produce energy. Like coenzyme Q-10, acetyl-L-carnitine enhances neuronal energy production by functioning as a 20 shuttle - transporting fuel sources into mitochondria, the energy producing machinery of the neuron. It also assists in removing toxic by products of brain metabolism and acts as a potent antioxidant. Acetyl-L-carnitine has been demonstrated to protect laboratory animals from developing full-blown Parkinsonism when exposed to specific chemicals know to induce the disease.
N-ACETYL L-TYROSINE
AT-Acetyl 1-Tyrosine, an acetylated form of 1-tyrosine, is converted in the body to key biologic compounds, including the neurotransmitters dopamine, norepinephrine and epinephrine. These neurotransmitters, collectively known as the catecholamines, are critically important for a sense of "readiness" to meet life challenges. Catecholamines are 30 produced in the adrenal glands, and are primary players in mediating our bodies' response to stress.
130I10NZ Prov.doc/CA/ca
There is some evidence that 1-tyrosine or its catecholamine metabolites are necessary for the production of coenzyme Q10, a cofactor in the electron-transport chain, a process that occurs in every cell of the body and results in the synthesis of the energy-generating molecule ATP. It is also involved in the production of thyroid hormones, important metabolism regulators, 5 and melanin, the skin pigment that protects us from ultraviolet radiation. Source Naturals N-Acetyl 1-tyrosine combines this remarkable nutrient with the B vitamins pyridoxine (B6) and folic acid to assist its conversion to its various metabolic products
PHOSPHATIDYL CHOLINE
Phosphatidyl choline is an important phospholipid which contains the B vitamin-like 10 substance choline. It is a principal component of cell membranes, found in virtually every cell in the body. In addition, it is an important precursor to the neurotransmitter acetylcholine, which is associated with memory and muscle control.
Soy lecithin also contains the essential cell membrane phospholipids phosphatidyl inositol, phosphatidyl ethanolamine and related phosphorus-containing lipids.
PHOSPHATIDYL SERINE COMPLEX
Phosphatidyl serine (PS) is a key cell membrane phospholipid, which is essential for normal neuron structure and function. Phospholipids are fat-like substances containing a hydrophilic (water-loving) phosphate-based head group (which forms the outward surface of the cell membrane) and two hydrophobic (water-hating) fatty acid tails (which form the inner surface 20 of the cell membrane). PS readily crosses the blood-brain barrier, promoting entry into the brain.
Phospholipids are the primary structural component of all cell membranes, and cells depend on the maintenance of a certain combination of them for proper function. This is a particularly important issue with regards to neuron function, as nerve impulses are 25 transmitted across the neuronal membrane.
Phosphatidyl serine, because of its particular chemical structure, associates preferentially with a class of membrane-bound proteins called ATPases. ATPases regulate, among other things, the balance of sodium and potassium in intra- and extracellular fluids, a balance that is necessary for the integrity of our cells and also for the electrochemical impulses that make
130110NZ Prov.doc/CA/ca
up our thoughts and feelings. Without phosphatidyl serine, these vitally important membrane-embedded proteins could not function. Another factor in the importance of PS is that it can be converted to the acetylcholine precursor phosphatidyl choline, thus possibly supporting optimal acetylcholine levels in the brain.
The composition of cell membrane phospholipids changes as we age; this change is a factor in age-related cognitive decline. Extensive studies have shown that supplementing the diet with PS helps to maintain the proper balance of phospholipids in nerve cell membranes as we age.
Research carried out at Stanford University evaluating 149 patients suffering from dementia 10 demonstrated that orally administered phosphatidylserine produced a marked improvement on performance tests related to memory and learning in demented patients. Like acetyl-L-carnitine and coenzyme Q-10, phosphatidylserine plays an important role in maintaining the ability of brain neurons to produce energy. Phosphatidylserine is a fundamental component of the fatty membranes surrounding the mitochondria where energy production occurs. In 15 addition, it also serves as a critical component of the membrane surrounding neurons and thus plays a fundamental role in the process by which brain cells both receive and transmit chemical messages.
Vitamin B1 and Magnesium
Two nutrients, which are intimately involved in many aspects of nerve health and function. 20 The major coenzyme form of vitamin Bl, thiamine pyrophosphate (TPP), is necessary for the conversion of pyruvate into acetyl CoA, a key step in the Krebs cycle. This step is pivotal for the production of energy, and is also essential for the production of acetylcholine, a key neurotransmitter associated with memory and muscle control. Thiamin is also maintains the myelin sheath, the protective coating that shields the axons of nerve cells and assists in the 25 transmission of the nerve impulses along their length. Magnesium plays an important role in nerve cell function and neuromuscular transmission and activity. Magnesium also promotes muscle relaxation. Excessive alcohol intake as well as black tea and coffee intake increase the requirements for thiamin and magnesium, this important mineral is critical in a program designed to preserve and enhance brain function for several important reasons. First, 30 adequate amounts of magnesium are necessary for the electrical depolarization of the neuronal membrane. This is the process by which chemical messages are transmitted from
130110NZ Prov.doc/CA/ca
one neuron to the next. Next, magnesium enhances the function of various brain antioxidants thus helping to protect the brain against free radical damage. Finally, magnesium helps to prevent the production of specific chemicals within the body, which increase inflammation. In Alzheimer's disease, Parkinson's disease, and multiple sclerosis, inflammation represents 5 a fundamental mechanism enhancing the formation of brain damaging free radicals.
Dimethylaminoethanol Bitartrate
Dimethylaminoethanol, or DMAE, is an important neuroceutical, which may have beneficial effects on cognitive function and nerve cell membrane integrity. DMAE is a natural substance found in several foods, including sardines and anchovies.
DMAE is a precursor for the B vitamin-like substance choline. The neurotransmitter acetylcholine is formed from choline and acetyl CoA, a coenzyme form of vitamin B5. Acetylcholine is an important neurotransmitter, necessary for memory and muscle control. DMAE has been shown to increase levels of free choline in the brain, which is necessary for optimal production of acetylcholine. It crosses the blood-brain barrier more easily than 15 choline, directly accessing the tissues of the brain where it is needed most.
DMAE also acts as an antioxidant, as it neutralizes a free radical known as the hydroxyl radical. In this way, DMAE helps stabilize cell membranes and promotes healthy nerve cell conduction, important goals in maintaining healthy brain function as we age.
Gamma Amino Butyric Acid
Gamma amino butyric acid, or GABA, is an amino acid. GABA is the primary inhibitory neurotransmitter in the brain; this means that rather than stimulating neurons to fire, GABA inhibits neuronal activity. Inhibitory neurotransmitters are important because they prevent the brain from being overloaded by stimuli. Thus GABA is associated with mental states of calm and serenity. GABA also promotes muscle relaxation.
Ginkgo biloba Extract 24%
Lipid peroxidation is a critical issue for brain health for several reasons. First, aside from water, the brain is composed primarily of lipids. The health of cell membranes in the brain is critical because the transmission of nerve impulses depends on electrochemical gradients,
130110NZ Prov.doc/CA/ca
which can only function properly if these membranes are intact. This includes the myelin sheath, the fatty insulation covering the axons of most neurons, the integrity of which is essential for proper nerve impulse conductivity. Also, free radical damage to cell membranes directly contributes to the buildup of lipofuscin or "age pigment" which some researchers 5 believe may contribute to age-related cognitive decline.
Ginkgo has been shown in numerous studies to dilate blood vessels and enhance their strength and flexibility. This is particularly important for the brain: much of the blood supply upon which the brain depends is carried by tiny, fragile capillaries, with a diameter so small that red blood cells can only pass through one at a time, single file. In addition to 10 strengthening and dilating blood vessels, ginkgo inhibits platelet stickiness, thus "thinning the blood" and further enhancing blood flow.
L-PYROGLUTAMIC ACID
1-Pyroglutamic acid (also called 2-oxo-pyrrolidone carboxylic acid or 1-PCA) is a cyclized derivative of the amino acid glutamate. Aside from functioning as an amino acid, glutamate 15 is also the most abundant excitatory neurotransmitter in the central nervous system, and may play a role in learning and memory. 1-Pyroglutamic acid is also a precursor to the important inhibitory neurotransmitters glycine and GABA, which are associated with the mental states of calm and serenity.
In addition, 1-pyroglutamic acid is associated with the activity of the key neurotransmitter 20 acetylcholine (ACH), necessary for muscle control and memory. Studies show that orally administered 1-pyroglutamic
Boron
Studies have shown that a low boron diet influences brain waves. They have shown when subjects ate less boron they were less alert.
Vitamin E
Of the various types of chemicals found within the body, fat is the most susceptible to being damaged by free radicals. This explains why the brain, having such a high content of fat, is at such an increased risk for free radical damage. Vitamin E is a "fat soluble" antioxidant meaning that its protective effect is most realized in tissues with a high fat content - like the 30 brain. Indeed, diets rich in natural sources of vitamin E are associated with a reduction in the
130110NZ Prov.doc/CA/ca
risk of Parkinson's disease. In individuals already given the diagnosis, the progression of Parkinson's disease has been dramatically slowed with vitamin E and C supplementation.
Alpha Lipoic Acid
This is a powerful antioxidant able to regenerate important brain antioxidants including 5 vitamins E, C, and glutathione. Unlike other antioxidants, alpha lipoic acid is both fat-soluble and water-soluble. This greatly enhances its ability to be absorbed from the gut and permits increased penetration into the brain.
N-Acetyl-L-Cysteine (NAC)
While glutathione represents one of the most important of the brain's antioxidant's defenses, it is generally considered useless when given orally. NAC is readily absorbed from the gut and dramatically increases the body's production of brain protecting glutathione. The ability of NAC to increase brain glutathione is enhanced in the presence of adequate amounts of vitamin C and E. In addition to enhancing glutathione production, NAC itself is a potent antioxidant and has been demonstrated to reduce the formation of the free radical nitric oxide, which has been implicated as having a causative role in Parkinson's disease, Alzheimer's disease, and several other neurodegenerative disorders.
Vitamin B12 (Cyanocobalamin)
Deficiency of vitamin B12 has been associated with mental slowness, confusion, depression, memory difficulties, and abnormalities of nerve function, Alzheimer's disease, and multiple sclerosis. Not only is vitamin B12 critical for the maintenance of myelin, the protective insulating coat surrounding each neuron, but it also helps reduce the level of a particular amino acid, homocysteine, which has been associated with increased risk for Alzheimer's disease, stroke, and myocardial infarction.
Folic Acid
A large number of studies have confirmed a direct relationship between folic acid status and various neurological problems including dementia, memory loss, and even depression. Like vitamin B12, the importance of folic acid in preserving normal brain function likely stems from its role in reducing homocysteine. Homocysteine is a toxic amino acid, elevation of which is associated with more rapid deterioration in some forms of dementia as well as a 30 dramatic increase in stroke risk.
130110NZ Prov.doc/CA/ca
Niacin (as niacinamide)
Like pyridoxine, niacin is a B vitamin and a key cofactor in the fundamental process of brain cell energy production. Deficiencies of niacin can profoundly affect brain cell metabolism resulting in dementia.
Pyridoxine
Pyridoxine is a B vitamin critical for maintenance of adequate cellular metabolism. Its role in preserving brain function has been demonstrated in several studies showing a direct relationship between low levels of pyridoxine and severity of dementia. Like folic acid and B12, pyridoxine helps reduce homocysteine.
Rosemary extracts 6% carnosic acid
Carnosic acid standardized rosemary extract to be as effective as activin (grape seed extract) and pycnogenol and twice as effective as vitamin E at inhibiting the oxidation of cholesterol in human aortic endothelial cells. This and other studies prove Carnosic acid to be an effective fat-soluble antioxidant. Brain tissue is mostly fat.
The following example is a preferred embodiment of the present invention and shows a composition in the form of an oral composition (tablet form) and the constituent components that go into making that composition. Of course, in alternative embodiments not described, any appropriate selection or combination of the component parts used in the formulation of the oral composition of the example given below, could be used to form alternative 20 compositions, that could be oral compositions in the form of tablets or fluids or injectable compositions.
13011ONZ Prov.doc/CA/ca
Each tablet contains:
Vitamins and Minerals
Vitamin A (as Beta-Carotene)
About 1 mg 1000IU
%USRDA
%
Vitamin B1 (Thiamine) as Thiamin Mononitrate, or HC1)
mg
Vitamin B2 (Riboflavin)
mg
Vitamin B3 (Inositol Hexanicotinate 100 mg & Niacinamide 50 mg)
Vitamin B5 (Pantothenic Acid, or D-Calcium Pantothenate)
mg
mg
Vitamin B6 (Pyridoxine HC1) 10 mg
Vitamin B12 (Cyanocobalamin) 25 meg
Folic Acid 400 meg
Biotin 50 meg
Vitamin C (Calcium, or Zinc Ascorbates)
mg
Vitamin E (D-Alpha Tocopheryl Succinate, or Acetate) U
I
666% 586% 100%
500%
500% 420% 50% 17%
32% 100%
Calcium (Ascorbate, or Carbonate, or Malate, or Succinate)
50 mg
%
Magnesium (Malate, or Succinate, or^Omg
12.5%
130110NZ Prov.doc/CA/ca
Taurinate, or Oxide)
Zinc (Ascorbate) 10 mg 67%
Manganese (Citrate) 5 mg *
Selenium (Sodium Selenite) 50 meg 72%
Boron (Citrate) 250 meg *
Copper (Sebacate) 0.5 mg 25%
Molybdenum (Sodium Molybdate) 25 meg 33%
Chromium ( Chromium Chloride, or
50 meg 42%
Nicotinate)
* U.S. RDA not established.
Amino Acids & Other Ingredients:
*
L-Pyroglutamic Acid 80 mg
*
L-Glutamine 100 mg
*
Acetyl L-Carnitine , or L-Carnitine 100 mg
DMAE (Dimethylaminoehtanol *
40 mg
Bitartrate)
Taurine (L-Taurine, or Magnesium *
mg
Taurinate)
DLPA (DL-Phenylalanine) 30 mg
*
Phosphatidyl-Choline lOOmg
*
Phosphatidyl-Ethanolamine 25 mg
Choline (Bitartrate) 40 mg
130110NZ Prov.doc/CA/ca
N-Acetyl L-Tyrosine, or L-Tyrosine 80 mg GABA (Gamma Amino Butyric Acid) 30 mg
PAK (Pyridoxine alpha-Ketoglutarate) 20 mg
Ginkgo biloba Leaf Extract (with 24% Ginkgo Flavone Glycosides from 1500
mg mg Ginkgo Biloba Leaf in a 50:1 concentration)
Phosphatidyl-Inositol, or Inositol 30 mg
Lipoic Acid 10 mg
Phosphatidyl Serine 25 mg
DHA powder (docosahexaenoic acid) 20 mg Huperzine A (huperzia serrata club moss)
meg
Standardized Herbal Extracts Formula 200 mg
(Siberian Ginseng, 25 mg; Gotu Kola, 25 mg; Ginger Root, 25 mg; Schizandra, 25 mg; & Cayenne, 25 mg; Grape Seed Extract 25 mg, and Bacopa monniera (water hyssop), or Rosemary, 50 mg)
Total active ingredients = 1207 mg
Excipients 293 mg
Weight of one Tablet = 1500 mg
130110NZ Prov.doc/CA/ca
Excipients / One Tablet
Microcrystalline Cellulose 2-6% = 100 mg.
Mg Stearates / Stearic Acid 2-6% = 20 mg.
Silicon Dioxide 1-3% = 15 mg
Hydroxypropylcellulose 0.5-2.5% = 30 mg.
Sodium Carboxymethylcellulose 0.5-2% = 33 mg.
Maltodextrin/or/Fructose 2-6% = 55 mg. OR FOS (FructoOlogoSaccharides.
Talc 2-5% = 40 mg.
293 mgs.
Example
1207 mg. Ingredients + 293 mg. Excipients = One Tablet 1500 mgs. Weight The shape of the tablet is Capsule-Shape Maximum length = 20 mm.
Maximum Width = 9 mm 20 Maximum Thickness = 8 mm.
Maximum Weight 1500 mgs. + 3% = 1545 mgs.
Minimum Weight 1500 - 3% = 1455 mgs.
Direct press tabletting process (Direct Compaction)
The Tablets to be coated by any thin film polymer, if required.
Suggested Use: Two to Four tablets daily between meals. If digestive irritation occurs, take with meals. Or, take as recommended by your health care professional.
MIXING PROCESS:
Recommended Procedure;
1/. Combine all ingredients in Phase A (Herbal Extracts) in order listed with
130110NZ Prov.doc/CA/ca
mixing, under very low humidity (less than 40%).
21. Combine all ingredients in Phase B (Vitamins) in order listed with mixing, under very low humidity (less than 40%).
3/. Separately combine ingredients in Phase C (Trace elements) and 5 ensure fully mixed.
4/. Combine all ingredients in Phase C (Minerals) in order listed with mixing, under very low humidity (less than 40%).
/. Separately combine ingredients in Phase D (Amino Acids) and ensure fully mixed.
6/. Combine all ingredients in Phase D (Supplements) in order listed with mixing, under very low humidity (less than 40%).
7/.Add premixed Phase An ingredients in large mixer (e.g., Sigma, or Cubic Mixer) and by continuous mixing adds the other premixed Phases B, C, and D in order listed- ensure fully mixed.
8/. Ideally homogenize or mill (as required) prior to pressing process to tablets, similar to Male tablets.
Research documents that ginkgo can improve the retention of learned behaviour, in other words, short-term memory formation. It can also enhance mental alertness and general cognitive performance and gently elevate mood.
One explanation for the herb's ability to boost memory power is that ginkgo is an antioxidant, meaning it scavenges the blood for harmful free radicals (toxins) which would otherwise damage or destroy brain cells. Another reason is that ginkgo improves blood flow to the brain. Increased circulation to the brain means that more blood sugar (the prime energy
130110NZ Prov.doc/CA/ca
source) can be delivered to brain cells, thereby increasing mental alertness. Greater blood flow also means increased oxygen availability to brain cells
In addition to ginkgo, PS, and DHA, contains other substances known to benefit brain function. Folic acid enhances brain blood circulation. Vitamin B12 is an essential component 5 in the protective wrapping (myelin sheath) around nerve fibers; B12 deficiencies are associated with poor memory and reasoning skills, and age-associated cognitive decline. Acetyl-L-carnitine (an amino acid) enhances energy production in the mitochondria (cellular energy "factories") of brain cells and improves communication across the brain hemispheres.
The product offers PS, DMAE, acetyl-L-carnitine, choline, ginkgo, glutamine, and 10 pyroglutamic acid, but adds to this mixture several other useful substances. Provides the "full potency therapeutic dosages, as based on clinical research, in each tablet. Ashwaganda, an herb from Indian Ayurvedic medicine, is included for its antiaging benefits; when the body ages quickly or even prematurely, brain function is inevitably affected, so slowing the aging process in itself helps maintain cognitive abilities.
Gotu kola is considered a "fountain of youth herb" in Chinese herbology; in Ayurvedic medicine, it is an energy tonic believed to strengthen brain cells and stimulate mental alertness.
Glutamine is one of the most prevalent amino acids found in the brain. It functions as a neurotransmitter that is a major fuel source for the brain and the entire body.
Choline is a nutrient needed for producing neurotransmitters,
Minerals such as calcium and magnesium are included to form neural electrolytes involved in the flow of electricity through the brain; the antioxidant vitamins A and E help protect nerve cell membranes against damage by toxins and free radicals and aid in the transmission of nerve cell signals; and the amino acid DL-phenylalanine is a key building block for the 25 neurotransmitter norepinephrine, enabling nerve cells to communicate. The nutrients, working together, produce a synergistic benefit and an action that surpasses the contributions of the individual nutrients acting alone, "Fatty acids play a key role in brain health and disease because they are so abundant in nervous tissue, including the bran's gray matter and white matter and the myelin sheaths. Fatty acids are the building blocks for neuron cell
13011ONZ Prov.doc/CA/ca
membranes (as well as phospholipids, which are made of fatty acids plus phosphorus and glycerol) and help protect brain cells from damage by toxins. Fatty acids not only affect the structural integrity of brain cell membranes, but they influence the way these cells make connections with neurotransmitters.
Phosphatidyl serine (PS) is a large fat molecule found in trace amounts in lecithin, derived from soybeans. While it's present throughout the body, its levels are especially high in nerve cell membranes. Although the brain normally produces enough PS, if the diet is deficient in essential fatty acids, or vitamins such as folic acid and B12, PS production may be blocked.
The one of the main component of this supplement (derived from micro algae) is DHA 10 (docosahexaenoic acid), the primary structural fatty acid in the retina of the eye and the gray matter of the brain. (DHA, which is an omega-3 long-chain fatty acid, is unrelated to DHEA, which is a hormone.) That explains why adequate levels of DHA are required for proper brain and eye development and function. In fact, about 60% of the brain is made of fats, of which DHA is the most abundant.
DHA is believed to assist nerve cells in the brain, retina, and elsewhere in the nervous system in sending messages to other cells by way of electrical current. According to Martek, this vegetable oil form of DHA "closely matches" the DHA found in human breast milk.
Neurotransmitters and Brain Chemical Precursors—A neurotransmitter is a brain chemical with the specific function of enabling communications to happen between brain cells, called 20 neurons. Electrical thought impulses are changed into neurotransmitters at the dendrites, the branching tips of a nerve cell; then they are passed on to the next nerve cell. Among the 100 neurotransmitters identified to date, six are involved in most mental activities.
This product supplies DMAE, a key precursor to the neurotransmitter acetylcholine. DMAE stands for di-methyl-aminoethanol, a substance naturally found in anchovies and sardines 25 and believed to slow down, possibly prevent, mental deterioration and memory loss, and to elevate concentration and learning ability. DMAE does this primarily by helping the body create acetylcholine, which is required for short-term memory storage and recall and communication between the brain and all body muscles.
130110NZ Prov.doc/CA/ca
This product included multiple-nutrient formula provides vitamins (B complex and C), minerals (magnesium, manganese, and zinc), herbal extracts and 12 neuronutrients such as DMAE, several amino acids and antioxidants, and phosphatidyl choline as neurotransmitter precursors, all essential to acetylcholine synthesis, as well as several amino acids intricately 5 involved in brain function: L-glutamine (a precursor for glutamic acid, a neurotransmitter which switches on brain activity) and L-pyroglutamic acid (which activates brain cells that use acetylcholine).
Huperzine A is an isolated alkaloid compound derived from Chinese club moss {Huperzia serrata or Club moss). In traditional Chinese medicine the dried or fresh herb was boiled in water, strained and consumed as a tea for kidney and bladder complaints, as well as a treatment for fevers and inflammation. Though there are toxicities associated with the consumption of the whole herb, the purified Huperzine an alkaloid is proven safe. , Blocks the enzyme that otherwise breaks down acetylcholine.
Gotu kola (centella asiatica) has been traditionally used as a neural tonic that slowly supports mental stamina and brain
The intention underlying this combination is to enhance brain energy metabolism. ADVANTAGES
The present invention provides a composition that is more effective as a health supplement because the components that go into making the composition act in a synergistic fashion to produce an improved health supplement.
Throughout the description and claims of this specification, the word "comprise and variations of that word such as "comprises" and "comprising" are not intended to exclude other additives, components, integers or steps.
Furthermore, this invention may broadly be said to consist in the parts elements and features 25 referred to or indicated in the specification of the application, individually or collectively and any or all combinations of any two or more of the parts, elements or features, and where specific integers are mentioned herein which have known equivalents are deemed to be incorporated herein as if individually set forth.
£ 20
130110NZ Prov.doc/CA/ca
Claims (64)
1. A composition suitable for administering to warm blooded animals as a health supplement including pyridoxine alpha ketoglutarate and acetyl L-carnitine wherein the composition further includes at least one plasmalogen phosphalide, an inositol, and extract of ginko 5 biloba.
2. A composition as claimed in claim 1, wherein the or each plasmalogen phosphalide can be selected from the group comprising phosphatidyl choline and phosphatidyl ethanolamine.
3. A composition as claimed in claim 1 or claim 2, wherein the or each inositol can be selected from the group comprising phosphatidyl inositol and inositol. 10
4. A composition as claimed in any preceding claim, wherein the composition further comprises vitamins.
5. A composition as claimed in claim 4, wherein the vitamins can be selected from the group comprising A, C, E and a B complex.
6. A composition as claimed in claim 5, wherein the vitamin B complex can be selected from 15 the group comprising Bl, B2, B3, B5, B6 and B12.
7. A composition as claimed in any preceding claim, wherein the composition further comprises a metal derivative.
8. A composition as claimed in claim 7, wherein the metal derivative can be selected from the group comprising mono, di, tri and tetra valent metal derivatives. 20
9. A composition as claimed in claim 8, wherein the divalent metal derivative can be selected from the group of metals comprising calcium, zinc, copper, manganese, chromium and magnesium.
10. A composition as claimed in the preceding claim, wherein the divalent metal derivative can be selected from the group comprising calcium ascorbate, carbonate, nicotinate, 25 sebacate, chloride, malate, taurinate, oxide,citrate or succinate. 130110NZ Prov.doc/CA/ca -24-
11. A composition as claimed in claim 8, wherein the trivalent metal derivative can be selected from the group of metals comprising boron and chromium.
12. A composition as claimed in the preceding claim, wherein , the trivalent metal derivatives can be selected from the group comprising chloride, nicotinate and citrate. 5
13. A composition as claimed in claim 8, wherein the monovalent metal derivative can be selected from the group of metals comprising potassium, sodium and lithium.
14. A composition as claimed in the preceding claim, wherein the monovalent metal derivatives can be selected from the group comprising selenite and molybdate.
15. A composition as claimed in any preceding claim, wherein the composition further 10 comprises an amino acid.
16. A composition as claimed in the preceding claim, wherein the amino acid can be selected from the group comprising L-glutamine, Taurine, N-acetyl L-Tyrosine, and L-Tyrosine.
17. A composition as claimed in any preceding claim, wherein the composition further comprises at least one of the following, L-Pyroglutamic acid, 15 dimethylaminoethanolbitartrate, DL-phenylalanine, choline bitartrate, liopic acid, docosahexaenoic acid, folic acid, biotin, huperzine and/or phosphatidyl serine.
18. A composition as claimed in any preceding claim, wherein the composition further comprises one or more herbal extracts.
19. A composition as claimed in the preceding claim, wherein the herbal extracts can be 20 selected from the group comprising Siberian ginseng, gotu kola, ginger root, schizandra, cayenne, grape sees extract, bacopa monniera and rosemary.
20. A composition as claimed in any preceding claim, wherein the composition further comprises an excipient.
21. A composition as claimed in the preceding claim, wherein the extract of Ginkgo biloba is 25 in the range of 1.0-5.0 x 10-3 %w/v. 130110NZ Prov.doc/CA/ca -25 -
22. A composition as claimed in any preceding claim, wherein the pyridoxine alpha ketoglutarate is in the range of 10-30 x 10-3 %w/v.
23. A composition as claimed in any preceding claim, wherein the acetyl L-carnitine is in the range of 40-150 x 10-3 %w/v. 5
24. A composition as claimed in any preceding claim, wherein the plasmalogen phosphalide is in the range of 50-200 x 10-3 %w/v.
25. A composition as claimed in any preceding claim, wherein the phosphatidyl choline is in the range of 40-150 x 10-3 %w/v.
26. A composition as claimed in any preceding claim, wherein the phosphatidyl 10 ethanolamine is in the range of 5-40 x 10-3 %w/v.
27. A composition as claimed in any preceding claim, wherein the inositol is in the range of 5-50 x 10-3 %w/v.
28. A composition as claimed in any preceding claim, wherein the phosphatidyl inositol is in the range of 5-50 x 10-3 %w/v. 15
29. A composition as claimed in any preceding claim, wherein the vitamin B complex is in the range of 30-150 x 10-3 %w/v.
30. A composition as claimed in any preceding claim, wherein the vitamin A is in the range of 2-20 x 10-4 %w/v.
31. A composition as claimed in any preceding claim, wherein the vitamin C is in the range 20 of 5-30 x 10-3 %w/v.
32. A composition as claimed in any preceding claim, wherein the folic acid is in the range of 100-600 x 10-3 %w/v.
33. A composition as claimed in any preceding claim, wherein the botin is in the range of 20-80 x 10-3 %w/v. 25
34. A composition as claimed in any preceding claim, wherein the calcium derivative is in the range of 20-80 x 10-3 %w/v 130110NZ Prov.doc/CA/ca -26-
35. A composition as claimed in any preceding claim, wherein the magnesium derivative is in the range of 20-80 x 10-3 %w/v.
36. A composition as claimed in any preceding claim, wherein the zinc derivative is in the range of 3-15 x 10-3 %w/v. 5
37. A composition as claimed in any preceding claim, wherein the manganese derivative is in the range of 2-8 x 10-3 %w/v.
38. A composition as claimed in any preceding claim, wherein the selenium is in the range of 20-80 x 10-3 %w/v.
39. A composition as claimed in any preceding claim, wherein derivative is in the range of 10 100-400 x 10-3 %w/v.
40. A composition as claimed in any preceding claim, wherein the copper derivative is in the range of 1-8 x 10-4 %w/v
41. A composition as claimed in any preceding claim, wherein the molybdenum derivative is in the range of 7-40 x 10-3 %w/v. 15
42. A composition as claimed in any preceding claim, wherein the chromium derivative is in the range of 20-80 x 10-3 %w/v.
43. A composition as claimed in any preceding claim, wherein the L-Pyroglutamic acid is in the range of 20-120 x 10-3 %w/v.
44. A composition as claimed in any preceding claim, wherein the L-glutamine is in the 20 range of 20-160 x 10-3 %w/v.
45. A composition as claimed in any preceding claim, wherein the acetyl L-carnitine is in the range of 20-160 x 10-3 %w/v.
46. A composition as claimed in any preceding claim, wherein the L-cartinine is in the range of 40-160 x 10-3 %w/v. 25
47. A composition as claimed in any preceding claim, wherein the dimethylaminoethanolbitartrate is in the range of 10-60 x 10-3 %w/v. 130110NZ Prov.doc/CA/ca -27-
48. A composition as claimed in any preceding claim, wherein the taurine is in the range of 5-50 x 10-3 %w/v.
49. A composition as claimed in any preceding claim, wherein the DL phenylalanine is in the range of 5-50 x 10-3 %w/v. 5
50. A composition as claimed in any preceding claim, wherein the choline is in the range of 20-50 x 10-3 %w/v.
51. A composition as claimed in any preceding claim, wherein the N-acetyl L-tyrosine is in the range of 20-120 x 10-3 %w/v.
52. A composition as claimed in any preceding claim, wherein the L tyrosine is in the range 10 of 20-120 x 10-3 %w/v.
53. A composition as claimed in any preceding claim, wherein the gama amino butyric acid is in the range of 5-50 x 10-3 %w/v.
54. A composition as claimed in any preceding claim, wherein the lipoic acid is in the range of 3-15 x 10-3 %w/v. 15
55. A composition as claimed in any preceding claim, wherein the phsphatidyl serine is in the range of 7-40 x 10-3 %w/v.
56. A composition as claimed in any preceding claim, wherein the docosahexaenoic acid is in the range of 8-30 x 10-3 %w/v.
57. A composition as claimed in any preceding claim, wherein the huperzine is in the range 20 of 7-40 x 10-3 %w/v.
58. A composition as claimed in any preceding claim, wherein the Siberian Ginseng is in the range of 7-40 x 10-3 %w/v.
59. A composition as claimed in any preceding claim, wherein the Gotu Kola is in the range of 7-40 x 10-3 %w/v. 25
60. A composition as claimed in any preceding claim, wherein the Ginger Root is in the range of 7-40 x 10-3 %w/v. 130110NZ Prov.doc/CA/ca §30554
61. A composition as claimed in any preceding claim, wherein the Schizandra is in the range of 7-40 x 10-3 %w/v.
62. A composition as claimed in any preceding claim, wherein the cayenne is in the range of 5 7-40 x 10-3 %w/v.
63 A composition as claimed in any preceding claim, wherein the grape seed extract is in the range of 7-40 x 10-3 %w/v.
64. A composition as claimed in any preceding claim, wherein the bacopa monniera or rosemary is in the range of 15-60 x 10-3 %w/v. 10 Andre Chissel 15 For PIPERS PATENT & TRADE MARK ATTORNEYS 20 INTELLECTUAL PROPERTY OFFICE OF N.Z 12 JAN 2004 RECEIVED Document2//ca
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ53055404A NZ530554A (en) | 2004-01-13 | 2004-01-13 | Neuronutrients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ53055404A NZ530554A (en) | 2004-01-13 | 2004-01-13 | Neuronutrients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ530554A true NZ530554A (en) | 2004-04-30 |
Family
ID=32501635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ53055404A NZ530554A (en) | 2004-01-13 | 2004-01-13 | Neuronutrients |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ530554A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016828A3 (en) * | 2004-08-12 | 2006-06-08 | Sgp & Sons Ab | Use of alpha ketoglutarate for treating alzheimer, parkinson |
| WO2008080333A1 (en) * | 2006-12-29 | 2008-07-10 | Pficker Pharmaceuticals Ltd. | Compound preparation for enhancing memory |
| EP1959977A4 (en) * | 2005-11-07 | 2010-03-31 | Russell M Jaffe | Compositions for regulating intestinal disorders and methods of use thereof |
| US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| US7976879B2 (en) * | 2005-11-04 | 2011-07-12 | Roizen Michael F | Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions |
| EP2269649A3 (en) * | 2004-08-26 | 2011-08-10 | Merz Pharma GmbH & Co. KGaA | Compositions containing a capillary active system with application-related differentiability, and the use thereof |
| US8110229B2 (en) * | 2008-04-19 | 2012-02-07 | Nisarga Biotech Pvt Ltd. | Herbal composition for reducing ADD/ADHD and method thereof |
| WO2014025905A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014047614A1 (en) * | 2012-09-24 | 2014-03-27 | Abbott Laboratories | Nutritional compositions and methods for enhancing cognitive function and muscle function |
| US20160158304A1 (en) * | 2011-07-12 | 2016-06-09 | Gregory Blackman | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication |
| ES2882361A1 (en) * | 2020-06-01 | 2021-12-01 | Nutraceutical Innovative Consulting S L | COMPOSITION FOR THE IMPROVEMENT OF COGNITIVE FUNCTION AND FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES IN A SUBJECT (Machine-translation by Google Translate, not legally binding) |
| US20220378731A1 (en) * | 2013-01-25 | 2022-12-01 | Tedone 3G Llc | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column |
| AU2022201543A1 (en) * | 2022-01-12 | 2023-07-27 | Visdon Pty Ltd | Brain-invigorating composition and preparation method thereof |
-
2004
- 2004-01-13 NZ NZ53055404A patent/NZ530554A/en unknown
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016828A3 (en) * | 2004-08-12 | 2006-06-08 | Sgp & Sons Ab | Use of alpha ketoglutarate for treating alzheimer, parkinson |
| EP1781330B1 (en) * | 2004-08-26 | 2013-03-27 | Merz Pharma GmbH & Co. KGaA | Compositions containing a capillary active system with application-related differentiability, and the use thereof |
| EP2269649A3 (en) * | 2004-08-26 | 2011-08-10 | Merz Pharma GmbH & Co. KGaA | Compositions containing a capillary active system with application-related differentiability, and the use thereof |
| US7976879B2 (en) * | 2005-11-04 | 2011-07-12 | Roizen Michael F | Nutritional supplement product to suppress age-related decline in cognitive capacity and other aging functions |
| EP1959977A4 (en) * | 2005-11-07 | 2010-03-31 | Russell M Jaffe | Compositions for regulating intestinal disorders and methods of use thereof |
| WO2008080333A1 (en) * | 2006-12-29 | 2008-07-10 | Pficker Pharmaceuticals Ltd. | Compound preparation for enhancing memory |
| US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| US8110229B2 (en) * | 2008-04-19 | 2012-02-07 | Nisarga Biotech Pvt Ltd. | Herbal composition for reducing ADD/ADHD and method thereof |
| US8394429B2 (en) | 2008-04-19 | 2013-03-12 | Nisarga Biotech Pvt. Ltd. | Herbal composition for reducing ADD/ADHD and method thereof |
| US10028991B2 (en) * | 2011-07-12 | 2018-07-24 | Gdb Patent Holdings, Llc | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication |
| US20160158304A1 (en) * | 2011-07-12 | 2016-06-09 | Gregory Blackman | Composition, and Method of Using the Composition, Effective for Minimizing the Harmful Effects Associated with Individuals Suffering from Alcohol Intoxication |
| AU2013299656C1 (en) * | 2012-08-07 | 2017-06-22 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014025905A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| WO2014047614A1 (en) * | 2012-09-24 | 2014-03-27 | Abbott Laboratories | Nutritional compositions and methods for enhancing cognitive function and muscle function |
| US20220378731A1 (en) * | 2013-01-25 | 2022-12-01 | Tedone 3G Llc | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column |
| ES2882361A1 (en) * | 2020-06-01 | 2021-12-01 | Nutraceutical Innovative Consulting S L | COMPOSITION FOR THE IMPROVEMENT OF COGNITIVE FUNCTION AND FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES IN A SUBJECT (Machine-translation by Google Translate, not legally binding) |
| AU2022201543A1 (en) * | 2022-01-12 | 2023-07-27 | Visdon Pty Ltd | Brain-invigorating composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11173138B2 (en) | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans | |
| US7445807B2 (en) | Agglomerated granular protein-rich nutritional supplement | |
| KR102702576B1 (en) | Composition | |
| WO2020092451A1 (en) | Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| Abud et al. | Taurine as a possible antiaging therapy: A controlled clinical trial on taurine antioxidant activity in women ages 55 to 70 | |
| NZ530554A (en) | Neuronutrients | |
| WO2003003981A2 (en) | Compositions for improving mental performance | |
| US20240285704A1 (en) | Compositions comprising organic mineral chelates, niacinamide, and hemp oil and uses thereof for neuroprotection, cardioprotection, detoxification, immune support, and anti-aging | |
| JP2008174512A (en) | Composition for ameliorating exhausted feeling at time of rising | |
| GB2585619A (en) | A supplement | |
| Hemat | Principles of orthomolecularism | |
| US20100056484A1 (en) | Dietary supplemental composition effective for enhancing cognitive performance, elevating mood and reducing oxidative stress | |
| US20050013884A1 (en) | Compositions and methods for treating heart disease | |
| US20210353578A1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
| IL177118A (en) | Use of lipophilic complexes in the manufacture of a medicament for treatment and prevention of cognitive function and the alleviation of mental fatigue and as a dietary supplement | |
| AU2022334961B2 (en) | Nutritional compositions | |
| US11147761B2 (en) | Topical supplement composition and method of use | |
| Nenseth et al. | A Nutraceutical Formula Is Effective in Raising the Circulating Vitamin and Mineral Levels in Healthy Subjects: A Randomized Trial | |
| US20200268775A1 (en) | Lipid supplements for reducing nerve action potentials | |
| WO2018039297A1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
| FR2838645A1 (en) | Reducing intracellular accumulation of lipids and treating obesity, by oral or local administration of synergistic combination of at least two vitamins and at least two minerals or trace elements | |
| US12496283B2 (en) | Administration of R-beta-hydroxybutyrate and related compounds in humans | |
| US12171735B2 (en) | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans | |
| KR20040088149A (en) | Brain activity nutrient material composition | |
| Batra | Vitamins B6, B9, and B12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |